Summary
Johnson & Johnson (JNJ) filed its 2007 Form 10-K on February 25, 2008, reporting on its fiscal year ended December 30, 2007. As a large accelerated filer, the company's filing provides a comprehensive overview of its business segments, financial condition, and risk factors. While specific financial performance figures are not detailed in the provided excerpt, the filing indicates JNJ operates across various business segments and geographies. The report emphasizes the company's adherence to regulatory requirements and provides extensive information on corporate governance, executive compensation, and legal proceedings, offering transparency to investors regarding the company's operations and management. The filing also highlights Johnson & Johnson's robust legal and compliance framework, referencing numerous exhibits related to its corporate structure, stock plans, and compensation arrangements. Investors can find detailed information regarding the company's market for its common stock and related stockholder matters in Part II. The company's significant market capitalization, exceeding $178 billion as of February 15, 2008, underscores its status as a major player in the pharmaceutical, medical devices, and consumer health products industries. This report serves as a critical resource for understanding JNJ's operational landscape and its commitment to investor disclosure.
Financial Highlights
33 data points| Revenue | $61.09B |
| Cost of Revenue | $17.75B |
| Gross Profit | $43.34B |
| SG&A Expenses | $20.45B |
| Interest Expense | $296.00M |
| Net Income | $10.58B |
| EPS (Basic) | $3.67 |
| EPS (Diluted) | $3.63 |
| Shares Outstanding (Basic) | 2.88B |
| Shares Outstanding (Diluted) | 2.91B |
Key Highlights
- 1Johnson & Johnson is a large accelerated filer, indicating significant size and reporting compliance.
- 2The company operates across diverse business segments and geographic areas.
- 3The filing references extensive exhibits detailing corporate structure, stock plans, and executive compensation, providing transparency.
- 4A significant market capitalization of approximately $178 billion as of February 15, 2008, reflects the company's substantial market presence.
- 5The report incorporates by reference portions of the 2007 Annual Report to Shareholders and the 2008 Proxy Statement for further details.
- 6The company emphasizes its adherence to regulatory requirements and maintains a comprehensive framework for legal and compliance matters.
- 7Information on the market for JNJ's common equity and related stockholder matters is detailed in Part II of the filing.